IP Library › Granted Patent US 11,034,701
Granted Patent B2
US 11,034,701 · App. 15/580,313 · Granted Jun 15, 2021

Drug delivery and imaging chemical conjugate, formulations and methods of use thereof

Inventors: Steven Jay Adelman (Doylestown, PA); H. Donlon Skerrett (Wayne, PA); William A. Kinney (Newtown, PA)
Assignee: NANOPHAGIX LLC
C07D491/153A61K47/542A61P1/00A61P9/10A61P19/02A61P29/00A61P35/00C07D491/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,034,701
App. No.
15/580,313
Granted
Jun 15, 2021
Kind
B2
Abstract

The present invention relates to compounds of Formula 1, and methods of use thereof, capable of entering macrophages. The invention further relates to compounds capable of modulating (for example inhibiting) the activity of the mammalian target of rapamycin (mTor), treating mTor-associated diseases, in particular, but not limited to, related to mTor in macrophages. The invention also relates to compounds capable of imaging mTor in a subject, in particular, but not limited to, mTor in macrophages. wherein Q is, in one embodiment,

Claims (10)

1. A compound represented by Formula 2:

2. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

3. The composition of claim 2 , wherein the compound is formulated into particles.

4. The composition of claim 3 , wherein the size of the particles ranges from 2000 nm to 5 nm.

5. The composition of claim 3 , wherein the size of the particles ranges from 200 nm to 5 nm.

6. The composition of claim 3 , wherein the size of the particles ranges from 140 nm to 80 nm.

7. A method of inhibiting mammalian target of rapamycin (mTor) in a subject suffering from a disease or disorder, comprising the step of administering to the subject a therapeutically effective amount of the compound of claim 1 .

8. The method of claim 7 , wherein the disease or disorder is at least one selected from the group consisting of atherosclerosis, sarcoidosis, an inflammatory disease, chronic obstructive pulmonary disease (COPD), emphysema, heart failure, vasculitis, rheumatoid arthritis, osteoarthritis, peripheral artery disease (PAD), sepsis, sepsis in late-stage cancer patients, ischemia, phlebitis, colitis, celiac disease, chronic inflammatory bowel disease, Crohn's disease, chronic prostatitis, interstitial cystitis, angiogenesis associated with tumor formation, cervical cancer, cardiomyopathy, and rhinitis.

9. A method of imaging mTor in a subject, comprising the step of administering to the subject an effective amount of the compound of claim 1 .

10. A method of inhibiting mammalian target of rapamycin (mTor) in a subject in need thereof, and of imaging mTor in a subject, comprising the step of administering to the subject a therapeutically effective amount of the compound of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2019
From: ADELMAN, STEVEN JAY; SKERRETT, H. DONLON; KINNEY, WILLIAM A.
To: NANOPHAGIX
Reel/Frame 049938/0436 →
Continuity (2)
Provisional Application 62180111 · Jun 16, 2015
Related Publication 20180162869A1 · Jun 14, 2018